Elicit: Impact of Tozinameran mRNA Design on Antigenicity
Impact of Tozinameran mRNA Design on Antigenicity
How does Tozinameran's mRNA design (e.g., prefusion-stabilized spike) affect antigenicity?
Tozinameran's prefusion-stabilized spike design (K986P/V987P mutations) and N1-methylpseudouridine modifications enhance antigenicity by concentrating immune responses on neutralizing epitopes and prolonging antigen expression, producing neutralizing antibody titers 10-18 times higher than natural infection despite recognizing fewer total epitopes.
Abstract
Tozinameran’s mRNA design achieves high antigenicity through multiple synergistic elements centered on prefusion-stabilized spike protein presentation. The K986P and V987P mutations lock the spike in a conformation where approximately 20% of trimers adopt the one-RBD ‘up’ state, authentically presenting the ACE2 binding site and neutralizing epitopes. This design elicits neutralizing antibody titers 10-18 times higher than convalescent sera in non-human primates and preserves neutralization against some variants, supported by clinical efficacy exceeding 95%. N1-methylpseudouridine modification enhances mRNA stability and translation while reducing innate immune sensing, contributing to the superiority of nucleoside-modified vaccines (>94% efficacy) over unmodified designs (48% efficacy). Additional elements including optimized UTRs and TENT5A-mediated poly(A) tail extension prolong antigen production and enhance immunogenicity.
Critically, the prefusion-stabilized design produces a distinct immune profile compared to natural infection: vaccine-elicited sera recognize fewer total linear epitopes (11 vs 37) but achieve higher neutralizing potency by focusing responses on functionally critical determinants like K417, E484, and N501 residues. The 26 epitopes recognized exclusively by convalescent sera map predominantly to post-fusion conformational states masked by prefusion stabilization, representing non-neutralizing targets. This epitope focusing represents an intentional design feature prioritizing neutralizing antibody quality over total antibody diversity. The design also generates strong TH1-type CD4+ and IFNγ+ CD8+ T-cell responses with broader epitope coverage from the full-length spike compared to RBD-only constructs. Advanced stabilization approaches like the S6P mutation further enhance durability and cross-variant neutralization, while self-amplifying platforms demonstrate sustained immune activation through prolonged antigen expression.
Methods
We analyzed 10 sources from an initial pool of 200, using 9 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.
Results
Characteristics of Included Studies
| Study | Full text retrieved? | Study type | Species | Primary focus | Sample size/characteristics |
|---|---|---|---|---|---|
| Annette B. Vogel et al., 2020 | Yes | Preclinical | Mice, rhesus macaques | BNT162b2 design and immunogenicity | Male rhesus macaques, 2-4 years old |
| Annette B. Vogel et al., 2021 | Yes | Preclinical | Mice, rhesus macaques | BNT162b1 vs BNT162b2 comparison | Male rhesus macaques, 2-4 years old |
| Lizhou Zhang et al., 2023 | Yes | Preclinical | Mice | Component comparison (Pfizer vs Moderna) | 7-week-old female BALB/c mice |
| Y. Bong et al., 2025 | Yes | Preclinical | Mice | S6P mutation effects | Balb/c and K18-hACE2 transgenic mice, 6-8 weeks old |
| Sascha Hein et al., 2021 | Yes | Observational (human sera) | Human | BNT162b2 vs CVnCoV comparison | Healthcare workers (BNT162b2), phase I participants (CVnCoV) |
| Annette B. Vogel et al., 2020a | Yes | Preclinical | Mice, rhesus macaques | BNT162b vaccine candidates | Male rhesus macaques, 2-4 years old |
| Sascha Hein et al., 2021a | Yes | Observational (human sera) | Human | Epitope recognition patterns | Vaccinated and convalescent individuals |
| P. Krawczyk et al., 2025 | Yes | Preclinical | Mice | Re-adenylation mechanisms | 6-14 week old mice |
| Kate S. Levine et al., 2025 | No (abstract only) | Clinical trial (Phase III) | Human | ARCT-154 vs BNT162b2 | Participants with 3 prior mRNA vaccine doses |
| Rein Verbeke et al., 2021 | Yes | Review | Multiple (review) | mRNA vaccine design and performance | Phase 3 clinical trial data |
The included studies spanned preclinical models (mice and non-human primates), human observational studies, clinical trials, and systematic reviews. Studies employed diverse vaccination schedules, with preclinical studies typically using prime-boost regimens at days 0 and 21, while human studies examined booster responses in previously vaccinated individuals.
mRNA Design Features of Tozinameran
Tozinameran (BNT162b2) incorporates several molecular design elements intended to enhance antigenicity. The vaccine encodes a full-length spike protein stabilized in its prefusion conformation through K986P and V987P substitutions, also referred to as P2 mutations. Structural analysis revealed that approximately 20% of expressed spike trimers adopt the one-RBD ‘up’, two-RBD ‘down’ conformation, which authentically presents the ACE2 binding site and other neutralizing epitopes.
The mRNA contains nucleoside modifications, specifically N1-methylpseudouridine (m1Ψ), which reduces innate immune sensing and enhances RNA translation. The construct includes a 100-nucleotide poly(A) tail, though one study noted BNT162b2 has a composite poly(A) tail structure. The 5’ untranslated region (UTR) derives from human hemoglobin α-globin (HBA1), while the 3’ UTR originates from AES-mtRNR1. Additional optimization includes non-coding sequence elements and a linker (A30LA70) to improve RNA stability and translational efficiency.
Comparative design studies revealed differences between Tozinameran and other mRNA vaccines. BNT162b2 employs the ionizable lipid ALC-0315, enzymatically incorporated Cap 1 for mRNA capping, and a prefusion-stabilized spike configuration. An alternative design, BNT162b1, encodes a soluble, secreted trimerized receptor-binding domain (RBD-foldon) rather than the full-length spike. Advanced stabilization approaches, such as the S6P mutation (incorporating KV986PP plus four additional proline substitutions at F817P, A892P, A899P, and A942P), have been explored in next-generation candidates.